Ichikawa T, Saeki Y, Tamiya T, Chiocca E A, Ohmoto T
Department of Neurological Surgery, Okayama University Medical School.
Nihon Rinsho. 2000 Apr;58(4):822-7.
Recent advances in recombinant nucleic acid technologies and the understanding of the molecular biology of diseases provide the basis for gene therapy's ability to impact on the clinical practice of medicine. Herpes simplex virus type 1 (HSV-1) has features that make it suitable as a vector for gene therapy. These properties include: 1) wide host range and high efficiency of gene transfer; 2) large transgene capacity which is provided by deletion of genes unnecessary for viral replication; 3) unique ability of entering a state of latency in neurons; 4) specific oncolytic effect of some mutants by deletion of certain early genes. Three types of vectors designed for gene therapy have been developed from this virus, termed replication-defective vectors, replication-conditional vectors and amplicon vectors. In this review, we describe the recent advances in HSV-1-based vector systems and their applications for gene therapy.
重组核酸技术的最新进展以及对疾病分子生物学的理解为基因治疗影响医学临床实践的能力提供了基础。单纯疱疹病毒1型(HSV-1)具有使其适合作为基因治疗载体的特性。这些特性包括:1)宿主范围广且基因转移效率高;2)通过缺失病毒复制不必要的基因提供大的转基因容量;3)在神经元中进入潜伏状态的独特能力;4)某些突变体通过缺失特定早期基因具有特异性溶瘤作用。已从这种病毒开发出三种用于基因治疗的载体,称为复制缺陷型载体、复制条件型载体和扩增子载体。在本综述中,我们描述了基于HSV-1的载体系统的最新进展及其在基因治疗中的应用。